Literature DB >> 33063465

In reply: Aspirin desensitization for aspirin-exacerbated respiratory disease in the era of biologics: Clinical perspective.

Joshua M Levy1, Merin Kuruvilla2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33063465      PMCID： PMC8136336          DOI： 10.1002/alr.22708

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN： 2042-6976            Impact factor:   3.858


× No keyword cloud information.
  9 in total

1.  A survey of aspirin desensitization practices among allergists and fellows in training in the United States.

Authors:  Jeremy D Waldram; Andrew A White
Journal:  J Allergy Clin Immunol Pract       Date:  2016-07-21

2.  Treatment practices for aspirin-exacerbated respiratory disease: analysis of a national insurance claims database.

Authors:  Lauren T Roland; Celeste Nagy; Heqiong Wang; Renee Moore; Katherine N Cahill; Tanya M Laidlaw; Sarah K Wise; John M DelGaudio; Merin Kuruvilla; Joshua M Levy
Journal:  Int Forum Allergy Rhinol       Date:  2019-11-06       Impact factor: 3.858

Review 3.  Contemporary management of chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease: an evidence-based review with recommendations.

Authors:  Joshua M Levy; Luke Rudmik; Anju T Peters; Sarah K Wise; Brian W Rotenberg; Timothy L Smith
Journal:  Int Forum Allergy Rhinol       Date:  2016-08-02       Impact factor: 3.858

4.  Aspirin desensitization for aspirin-exacerbated respiratory disease in the era of biologics: Clinical perspective.

Authors:  John V Bosso
Journal:  Int Forum Allergy Rhinol       Date:  2020-10-18       Impact factor: 3.858

5.  A case for multidisciplinary management of chronic rhinosinusitis with nasal polyposis.

Authors:  Devyani Lal; Larry Borish; Kara Y Detwiller; Stacey T Gray; Shyam Joshi; Robert C Kern; Tanya M Laidlaw; Michael J Marino; Spencer C Payne; Anju T Peters; Zachary M Soler; Matthew A Rank
Journal:  Int Forum Allergy Rhinol       Date:  2020-05-03       Impact factor: 3.858

6.  Benefits and harms of aspirin desensitization for aspirin-exacerbated respiratory disease: a systematic review and meta-analysis.

Authors:  Derek K Chu; Daniel J Lee; Keith M Lee; Holger J Schünemann; Wojciech Szczeklik; John M Lee
Journal:  Int Forum Allergy Rhinol       Date:  2019-09-13       Impact factor: 3.858

Review 7.  Biologics in chronic rhinosinusitis with nasal polyposis.

Authors:  Tanya M Laidlaw; Kathleen M Buchheit
Journal:  Ann Allergy Asthma Immunol       Date:  2019-12-09       Impact factor: 6.347

8.  Revision surgery rates in chronic rhinosinusitis with nasal polyps: meta-analysis of risk factors.

Authors:  Catherine A Loftus; Zachary M Soler; Sina Koochakzadeh; Vincent M Desiato; Frederick Yoo; Shaun A Nguyen; Rodney J Schlosser
Journal:  Int Forum Allergy Rhinol       Date:  2019-11-21       Impact factor: 3.858

Review 9.  Guidance for contemporary use of biologics in management of chronic rhinosinusitis with nasal polyps: discussion from a National Institutes of Health-sponsored workshop.

Authors:  Lauren T Roland; Timothy L Smith; Rodney J Schlosser; Zachary M Soler; Anju T Peters; Tanya M Laidlaw; Benjamin S Bleier; Vijay Ramakrishnan; Elina Toskala; David W Kennedy; Amber U Luong
Journal:  Int Forum Allergy Rhinol       Date:  2020-07-03       Impact factor: 5.426
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.